Bridging the gap
from target to lead
The success of next generation antibody drug development relies on comprehensive discovery technologies and strategies. YUMAB bridges the gap between research innovation and novel therapies. Our advanced
discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.
From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.
Contract research
and R&D services
YUMAB provides individually designed contract research projects for the discovery and the development of fully human antibodies, as well as R&D services for the engineering of antibodies.
Antibody
Libraries
Discover
Me!
Antibody
Discovery
Discover
Me!
Antibody
Engineering
Discover
Me!
Antibody
Humanization
Discover
Me!
Yumab key features
- Almost 30 years of expertise in antibody research
- Flexible business conditions
- Human-derived, universal libraries (>1011)
- Powerful in-vitro selection technology (also on cells)
- High throughput screening technology (also on cells)
- Antibody engineering by in-vitro evolution & bioinformatic design
- Compatibility with difficult targets
- Compatibility with all antibody formats
Events
09.04. – 10.04.2025 | DBT
Heidelberg, Germany
23.04. – 24.04.2025 | FOB US
San Diego, CA / USA
05.05. – 06.05.2025 | SBD Basel
Basel / CH
12.05. – 16.05.2025 | PEGS US
Boston, MA / USA
Our partners
YUMAB and InSCREENeX get funding for innovative Mammalian Display screening – Yumab
Plattform für die Entwicklung von
T-Zellrezeptor ähnlichen bispezifischen
T-Zellaktivatoren mit hohem Sicherheitsprofil zur Krebsbehandlung (safeTY-engager) – Entwicklung der Antikörperformate
